JP6397488B2 - ＲＯＲγ調節因子 - Google Patents
ＲＯＲγ調節因子 Download PDFInfo
- Publication number
- JP6397488B2 JP6397488B2 JP2016515522A JP2016515522A JP6397488B2 JP 6397488 B2 JP6397488 B2 JP 6397488B2 JP 2016515522 A JP2016515522 A JP 2016515522A JP 2016515522 A JP2016515522 A JP 2016515522A JP 6397488 B2 JP6397488 B2 JP 6397488B2
- Authority
- JP
- Japan
- Prior art keywords
- tetrahydroquinolin
- sulfonyl
- fluorophenyl
- hexafluoro
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *[C@@](C(F)(F)F)(c(cc1)cc(CC[C@@]2CC(O)=O)c1N2S(c(cc1)ccc1F)(=O)=O)O Chemical compound *[C@@](C(F)(F)F)(c(cc1)cc(CC[C@@]2CC(O)=O)c1N2S(c(cc1)ccc1F)(=O)=O)O 0.000 description 1
- QBLZQBOPZUOSEP-INIZCTEOSA-N CC(C)(C(NNC(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O)=O)O Chemical compound CC(C)(C(NNC(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O)=O)O QBLZQBOPZUOSEP-INIZCTEOSA-N 0.000 description 1
- BZJZPVQQQMJXRF-KRWDZBQOSA-N CN(C)C(Cc1nnc(C[C@H](CCc2cc(C(C(F)(F)F)(C(F)(F)F)O)ccc22)N2S(c(cc2)ccc2F)(=O)=O)[o]1)=O Chemical compound CN(C)C(Cc1nnc(C[C@H](CCc2cc(C(C(F)(F)F)(C(F)(F)F)O)ccc22)N2S(c(cc2)ccc2F)(=O)=O)[o]1)=O BZJZPVQQQMJXRF-KRWDZBQOSA-N 0.000 description 1
- CZCQPGVHVPRQGT-INIZCTEOSA-N N#CCc1nnc(C[C@H](CCc2cc(C(C(F)(F)F)(C(F)(F)F)O)ccc22)N2S(c(cc2)ccc2F)(=O)=O)[o]1 Chemical compound N#CCc1nnc(C[C@H](CCc2cc(C(C(F)(F)F)(C(F)(F)F)O)ccc22)N2S(c(cc2)ccc2F)(=O)=O)[o]1 CZCQPGVHVPRQGT-INIZCTEOSA-N 0.000 description 1
- QIOFTFKSLWHSSG-UHFFFAOYSA-N O=C(CC1Nc2ccccc2CC1)OCc1ccccc1 Chemical compound O=C(CC1Nc2ccccc2CC1)OCc1ccccc1 QIOFTFKSLWHSSG-UHFFFAOYSA-N 0.000 description 1
- UWAVEZLBRVSMCA-UHFFFAOYSA-N OC(C(F)(F)F)(C(F)(F)F)c(cc1CCC2)ccc1N2S(c(c(CC(NCC(CN1)OC1=O)=O)c1)ccc1F)(=O)=O Chemical compound OC(C(F)(F)F)(C(F)(F)F)c(cc1CCC2)ccc1N2S(c(c(CC(NCC(CN1)OC1=O)=O)c1)ccc1F)(=O)=O UWAVEZLBRVSMCA-UHFFFAOYSA-N 0.000 description 1
- UXZRPPYGZFZIEB-AWEZNQCLSA-N OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O Chemical compound OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O UXZRPPYGZFZIEB-AWEZNQCLSA-N 0.000 description 1
- HBNJOSMGIAZNMX-XJDOXCRVSA-N OCC(C[n]1nccc1C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)O Chemical compound OCC(C[n]1nccc1C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)O HBNJOSMGIAZNMX-XJDOXCRVSA-N 0.000 description 1
- YYGNTJLVXLCHGQ-BHWOMJMDSA-N OCC(Cc1nnc(C[C@H](CCc2cc(C(C(F)(F)F)(C(F)(F)F)O)ccc22)N2S(c(cc2)ccc2F)(=O)=O)[o]1)O Chemical compound OCC(Cc1nnc(C[C@H](CCc2cc(C(C(F)(F)F)(C(F)(F)F)O)ccc22)N2S(c(cc2)ccc2F)(=O)=O)[o]1)O YYGNTJLVXLCHGQ-BHWOMJMDSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361880391P | 2013-09-20 | 2013-09-20 | |
| US61/880,391 | 2013-09-20 | ||
| PCT/US2014/056197 WO2015042212A1 (en) | 2013-09-20 | 2014-09-18 | RORγ MODULATORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530213A JP2016530213A (ja) | 2016-09-29 |
| JP2016530213A5 JP2016530213A5 (2) | 2017-10-26 |
| JP6397488B2 true JP6397488B2 (ja) | 2018-09-26 |
Family
ID=51726859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515522A Expired - Fee Related JP6397488B2 (ja) | 2013-09-20 | 2014-09-18 | ＲＯＲγ調節因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9725443B2 (2) |
| EP (1) | EP3046906B1 (2) |
| JP (1) | JP6397488B2 (2) |
| CN (1) | CN105555768B (2) |
| WO (1) | WO2015042212A1 (2) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| JP6397488B2 (ja) | 2013-09-20 | 2018-09-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| AU2014365915C1 (en) * | 2013-12-19 | 2019-04-04 | Merck Patent Gmbh | Tetrahydro-tetrazolo[1,5-a]pyrazines as ROR-gamma inhibitors |
| ES2704460T3 (es) | 2014-01-06 | 2019-03-18 | Bristol Myers Squibb Co | Moduladores de ROR gamma de ciclohexilsulfona |
| JP6476205B2 (ja) | 2014-01-06 | 2019-02-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ修飾因子としてのヘテロ環式スルホン |
| WO2015103508A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | CARBOCYCLIC SULFONE RORγ MODULATORS |
| TWI705057B (zh) | 2014-10-30 | 2020-09-21 | 比利時商健生藥品公司 | 用作ＲＯＲγｔ調節劑之三氟甲基醇 |
| EP3212641B1 (en) | 2014-10-30 | 2018-12-05 | Janssen Pharmaceutica NV | Thiazoles as modulators of roryt |
| HRP20200016T1 (hr) | 2014-10-30 | 2020-03-20 | Janssen Pharmaceutica Nv | Amidno supstituirani tiazoli kao modulatori rorgamat |
| AR104555A1 (es) * | 2015-05-07 | 2017-07-26 | Bristol Myers Squibb Co | SULFONAS TRICÍCLICAS COMO MODULARES DE RORg |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑 |
| WO2017213210A1 (ja) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | 複素環化合物 |
| KR102506326B1 (ko) * | 2016-10-13 | 2023-03-03 | 브리스톨-마이어스 스큅 컴퍼니 | Ror 감마 조정제로서의 헤테로시클릭 술폰 |
| ES2929140T3 (es) | 2018-06-18 | 2022-11-25 | Janssen Pharmaceutica Nv | Imidazoles sustituidos con fenilo y piridinilo como moduladores de RORgammat |
| JP2021528398A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγＴのモジュレーターとしての６−アミノピリジン−３−イルピラゾール |
| JP2021528405A (ja) | 2018-06-18 | 2021-10-21 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール |
| EP3807261B1 (en) | 2018-06-18 | 2022-07-13 | Janssen Pharmaceutica NV | Pyridinyl pyrazoles as modulators of roryt |
| CN111635373B (zh) * | 2019-03-01 | 2022-07-12 | 山东轩竹医药科技有限公司 | 多环磺酰胺类RORγ调节剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
| US7741317B2 (en) * | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP2368886A1 (en) * | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
| WO2012064744A2 (en) | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
| WO2013064231A1 (en) * | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| WO2014062938A1 (en) | 2012-10-19 | 2014-04-24 | Bristol-Myers Squibb Company | Rory modulators |
| JP6407285B2 (ja) | 2013-09-09 | 2018-10-17 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| JP6397488B2 (ja) | 2013-09-20 | 2018-09-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ調節因子 |
| KR101544975B1 (ko) * | 2013-09-30 | 2015-08-18 | 주식회사 플라즈마트 | 임피던스 매칭 방법 및 임피던스 매칭 시스템 |
| JP6476205B2 (ja) | 2014-01-06 | 2019-02-27 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ＲＯＲγ修飾因子としてのヘテロ環式スルホン |
| WO2015103508A1 (en) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | CARBOCYCLIC SULFONE RORγ MODULATORS |
| EA030849B1 (ru) | 2014-01-06 | 2018-10-31 | Бристол-Маерс Сквибб Компани | ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ |
| ES2704460T3 (es) | 2014-01-06 | 2019-03-18 | Bristol Myers Squibb Co | Moduladores de ROR gamma de ciclohexilsulfona |
-
2014
- 2014-09-18 JP JP2016515522A patent/JP6397488B2/ja not_active Expired - Fee Related
- 2014-09-18 EP EP14784387.4A patent/EP3046906B1/en not_active Not-in-force
- 2014-09-18 US US15/022,673 patent/US9725443B2/en active Active
- 2014-09-18 WO PCT/US2014/056197 patent/WO2015042212A1/en not_active Ceased
- 2014-09-18 CN CN201480051836.2A patent/CN105555768B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3046906A1 (en) | 2016-07-27 |
| CN105555768A (zh) | 2016-05-04 |
| WO2015042212A1 (en) | 2015-03-26 |
| US9725443B2 (en) | 2017-08-08 |
| EP3046906B1 (en) | 2017-08-16 |
| CN105555768B (zh) | 2018-10-16 |
| US20160229844A1 (en) | 2016-08-11 |
| JP2016530213A (ja) | 2016-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6397488B2 (ja) | ＲＯＲγ調節因子 | |
| CN111757878B (zh) | 一种哒嗪类衍生物抑制剂、其制备方法和应用 | |
| JP6407285B2 (ja) | ＲＯＲγ調節因子 | |
| JP6775560B2 (ja) | Ｊａｋ阻害剤としてのビピラゾール誘導体 | |
| CN103443098B (zh) | 作为溶血磷脂酸受体的拮抗剂的化合物、组合物及其应用 | |
| EP2253625B1 (en) | Pyridazinones, the preparation and the use thereof | |
| CN1938307B (zh) | 9-取代的8-氧代腺嘌呤 | |
| CN106061947B (zh) | 环己基砜RORγ调节剂 | |
| US9637455B2 (en) | Heterocyclic sulfone RORγ modulators | |
| KR102726637B1 (ko) | 6-아미노이소퀴놀린의 일가-(산) 염 및 이의 용도 | |
| TW201720802A (zh) | B型肝炎核心蛋白質調節劑 | |
| AU2021389180A9 (en) | Heteroaryl carboxamide compound | |
| EP2804861B1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| WO2021213317A1 (zh) | Hpk1抑制剂及其制备方法和用途 | |
| JP2011526294A (ja) | ホスホジエステラーゼ１０阻害剤としての二置換フェニル化合物 | |
| JP2017537950A (ja) | ピロロピリミジン化合物 | |
| US20250066322A1 (en) | Substituted heterocyclic compounds | |
| JP7025555B2 (ja) | 一過性受容体電位ａ１イオンチャネルの阻害 | |
| CN106795152A (zh) | 蛋白激酶抑制剂 | |
| CA2861442C (en) | Piperazinyl pyrimidine derivatives, preparation method and use thereof | |
| WO2025079680A1 (ja) | 神経保護剤 | |
| WO2021129841A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| US20230075856A1 (en) | Cyclic sulfamide compounds for treatment of hbv | |
| TW200530197A (en) | Novel compounds | |
| WO2023019090A1 (en) | Inhibitors of 12/15-lipoxygenase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170915 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170915 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20180522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180718 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180828 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180831 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6397488 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |